Key result
Factor VIII/vWF concentrates resolve angiodysplasia-related GI bleeding in a von Willebrand type III patient.
Why the study?
Management of gastrointestinal bleeding in patients with von Willebrand disease and angiodysplasia is problematic and no treatment modality has been successful in all cases.
Does prompt administration of factor VIII/vWF concentrates improve gastrointestinal bleeding in patients with von Willebrand type III disease and small bowel angiodysplasia?
Case Report (n=1)
Does prompt administration of factor VIII/vWF concentrates improve gastrointestinal bleeding in patients with von Willebrand type III disease and small bowel angiodysplasia?
Early infusion of factor VIII/vWF concentrates may be an effective strategy for managing gastrointestinal bleeding in patients with von Willebrand type III disease and angiodysplasia.
May support prompt factor VIII/vWF use in vWD type III GI bleeding; hypothesis-generating and requires prospective confirmation.
The association between gastrointestinal angiodysplasia and von Willebrand disease was reported 30 years ago. The clinical course of patients with von Willebrand disease and angiodysplasia is characterized by numerous admissions to hospital for gastrointestinal bleeding necessitating transfusion with packed red cells, factor VIII and plasma. The management of these patients is problematic. Numerous treatments for the gastrointestinal bleeding have been proposed: surgery, electrocoagulation, laser photocoagulation, sclerotherapy, arteriography with embolization, immunoglobulins, oestrogens, and octreotide, but no treatment modality has been successful in all cases. We report a 66-year-old-female with small bowel angiodysplasia and von Willebrand type III disease in whom prompt administration of factor VIII/vWF concentrates was effective. Education of patients to recognize minimal gastrointestinal bleeding manifestations, periodical clinical visits and early infusion of factor VIII/vWF seems to be fundamental for the success of this therapy. A longer follow-up and the study of other patients are needed to confirm our observation.
No takes yet. Share an insight, caveat, or question.
Zanon et al. (2001) conducted a case report in Small bowel angiodysplasia and von Willebrand type III disease (n=1). Factor VIII/vWF concentrates was evaluated on Effectiveness in treating gastrointestinal bleeding. Prompt administration of factor VIII/vWF concentrates was effective in treating gastrointestinal bleeding in a patient with small bowel angiodysplasia and von Willebrand type III disease.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: